Table 3 Grade 1 or 2 injection site reactions (incidence ≥1% in one or more treatment groups)
Adverse event, n (%) | Study 1 | Study 2a | ||
|---|---|---|---|---|
| Â | V930 DNA-EP | V930 DNA-EP | V932 Ad | V932 Ad |
|  | 0.25 mg | 2.5 mg | 0.5 × 109vg/injection | 0.5 × 1011vg/injection |
| Â | (n=6) | (n=22) | (n=6) | (n=5) |
Injection site erythema | 1 (17) | 14 (64) | 0 | 3 (60) |
Injection site pain | 4 (67) | 9 (41) | 1 (17) | 4 (80) |
Injection site swelling | 1 (17) | 8 (36) | 1 (17) | 2 (40) |
Injection site bruising | 1 (17) | 1(5) | 0 | 0 |
Injection site papule | 0 | 1(5) | 0 | 0 |
Injection site rash | 0 | 1(5) | 0 | 1 (20) |